Navigation Links
Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
Date:7/3/2012

NEW YORK, July 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth

http://www.reportlinker.com/p0922677/Generics-in-the-Antivirals-Market-to-2018---Launch-of-Generic-Combivir-and-Patent-Expiry-of-Sustiva-Kaletra-and-Epivir-HBV-will-Drive-Volume-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth

 

Summary

GBI Research in its present report "Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth" describes generic market in antiviral therapeutics. This report covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics. Generics in antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018, largely due to series of patent expiries in the antiviral market. In 2010 generic HIV/AIDS therapeutic market sales contributes 46% market share in the total generic antiviral therapeutic market followed by generic herpes therapeutic market with 39.6% of market share. It is estimated that in 2010, generics accounted for 18.9% of market share in global antivirals market, and this market share is forecast to grow and reach 29.2% by 2018.

Generics in global antivirals market are estimated to be $4.2 billion in 2010 and are forecast to grow at a CAGR of 10.5% and reach $9.2 billion by 2018. From 2004, the market grew at a CAGR of 21.1% to reach $4.2 billion in 2010. Global generic antiviral market is comprised of revenues generated by various generic antiviral drugs. In 2010, it is estimated that generics in HIV market accounted for largest market share in total generic antivirals market. Generics in HIV market accounted for 46% of market share in total generic antivirals market in 2010, while generic herpes therapeutics accounted for 39.6% of market share. Generic influenza therapeutics accounted for 1% of total market share. Generic CMV market holds about 9.6% of share in total antiviral generic market, while generic hepatitis market accounted for only 3.9% of market share.

Series of patent expiries of key antiviral drugs will positively impact the market. Increase in patient population, reforms in government policies towards the use of generic drugs could be other major drivers of the market during the forecast period.

GBI Research projects that global generic HIV market will grow at a CAGR of 6.7% during 2010-2018. Growth in the market could be attributed to loss of patent exclusivity of key antiviral drugs. The market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. Launch of Combivir (lamivudine/Zidovudine) is expected soon, which can significantly influence the market.

GBI Research forecast's that global generic herpes market will grow at a CAGR of 9% during 2010-2018. Global generic herpes therapeutics market grew at a rapid rate of 32.4% from 2004 to 2010. The market revenue during this period was driven primarily by generic product such as acyclovir. In 2009, after patent expiry of Valtrex (valacyclovir), its generic equivalents were launched. In 2010, Famvir (famciclovir), potent antiviral from Novartis lost its patent exclusivity and its generic equivalents are currently available. In April, 2011, Mylan launched generic version of famciclovir.

 

Scope

- Data and analysis on the global generics in antivirals market

- Market forecasts for the global generics in antivirals market until 2018

- Market Data on geographical landscape including country wise coverage, cost of therapy, market size and market share.

- Key drivers and restraints that have created significant impact on the market.

- Competitive landscape of the global generics in antivirals market including top companies profiles. The key companies studied in this report are Teva Pharmaceuticals, Aurobindo Pharma, Mylan Inc and Watson Pharmaceuticals.

- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the global generics in antivirals market.

 

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches -

- Build effective strategies to launch their generics antiviral products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

 

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 10

2 Introduction 11

3 Generics in Antivirals Market to 2018 - Market Overview 12

3.1 Introduction 12

3.2 Generic in Antivirals Market, Global Revenues 14

3.2.1 Revenue 14

3.2.2 Annual Cost of Treatment 18

3.2.3 Treatment Usage Pattern 19

3.2.4 Drivers and Restraints for Generic Antiviral Market 21

4 Generics in Antivirals Market to 2018 - Geographical Landscape 23

4.1 The US 23

4.1.1 Revenue 23

4.1.2 Treatment Usage Pattern 24

4.2 Top Five Countries of Europe 26

4.2.1 Revenue 26

4.2.2 Treatment Usage Pattern 29

4.3 Japan 31

4.3.1 Revenue 31

4.3.2 Treatment Usage Pattern 32

5 Generics in Antiviral Market to 2018 - Therapeutic Landscape 34

5.1 Global Generic HIV Therapeutics Market 34

5.1.1 Introduction 34

5.1.2 Revenue 35

5.1.3 Annual Cost of Treatment 40

5.1.4 Treatment Flow Algorithm 41

5.1.5 Treatment Usage Pattern 42

5.1.6 Drivers and Restraints for Generic HIV Market 44

5.2 Global Generic Hepatitis Therapeutics Market 45

5.2.1 Introduction 45

5.2.2 Revenue 47

5.2.3 Annual Cost of Treatment 51

5.2.4 Treatment Flow Algorithm 52

5.2.5 Treatment Usage Pattern 53

5.2.6 Drivers and Restraints for Generic Hepatitis Market 55

5.3 Global Generic Herpes Therapeutics Market 56

5.3.1 Introduction 56

5.3.2 Revenue 58

5.3.3 Annual Cost of Treatment 62

5.3.4 Treatment Flow Algorithm 63

5.3.5 Treatment Usage Pattern 64

5.3.6 Drivers and Restraints for Generics in Herpes Therapeutics Market 66

5.4 Global Generic Cytomegalovirus Therapeutics Market 67

5.4.1 Introduction 67

5.4.2 Revenue 68

5.4.3 Annual Cost of Treatment 72

5.4.4 Treatment Usage Pattern 73

5.4.5 Drivers and Restraints for Cytomegalovirus Therapeutics Market 75

5.5 Global Generic Influenza Market 76

5.5.1 Introduction 76

5.5.2 Revenue 77

5.5.3 Annual Cost of Treatment 81

5.5.4 Treatment Flow Algorithm 82

5.5.5 Treatment Usage Pattern 83

5.5.6 Drivers and Restraints for Influenza Therapeutics Market 85

6 Generics in Antivirals Market to 2018 - Major Marketed Drugs Analysis 86

6.1 Major Generic Drugs in Antivirals Market 86

6.1.1 Ribavirin 86

6.1.2 Acyclovir 86

6.1.3 Valacyclovir 87

6.1.4 Famciclovir 87

6.1.5 Penciclovir 87

6.1.6 Didanosine 88

6.1.7 Lamivudine 88

6.1.8 Stavudine 88

6.1.9 Zidovudine 89

6.1.10 Zalcitabine 89

6.1.11 Amantadine 89

6.1.12 Rimantadine 90

6.1.13 Ganciclovir 90

6.1.14 Foscarnet 90

6.2 Major Marketed Products Expecting Loss of Patent Exclusivity 91

6.2.1 Introduction 91

6.2.2 Baraclude 92

6.2.3 Viread 92

6.2.4 Combivir 93

6.2.5 Sustiva 93

6.2.6 Kaletra 93

6.2.7 Reyataz 94

6.2.8 Epzicom 94

6.2.9 Prezista 94

6.2.10 Valcyte 95

6.2.11 Tamiflu 95

6.2.12 Atripla 95

6.2.13 Truvada 96

7 Generics in Antivirals Market to 2018 - Competitive Landscape 97

7.1 Competitive Profiling 97

7.1.1 Teva Pharmaceuticals 97

7.1.2 Aurobindo Pharma Ltd 98

7.1.3 Watson Pharmaceuticals 99

7.1.4 Mylan Inc 100

8 Generics in Antivirals Market to 2018 - Strategic Consolidations 101

8.1 Generics in Antivirals Market: Major Deals 101

8.1.1 Gilead Sciences Extends Licensing Agreement with Matrix Laboratories for Tenofovir, Elvitegravir, Cobicistat and Quad 101

8.1.2 Bristol-Myers Squibb Enters Into Co-Marketing Agreement with Matrix Laboratories 101

8.1.3 Tibotec Pharmaceuticals Enters Into Licensing Agreement with Matrix Laboratories for TMC278 102

8.1.4 Watson Pharmaceuticals Acquires Specifar Pharmaceuticals 102

8.1.5 Watson Enters into Licensing Agreement with Natco 102

8.1.6 Apotex Acquires Lareq Pharma from Industria Quimica Y Farmaceutica 102

8.1.7 Apotex Acquires Topgen from Zambon 103

8.1.8 Teva Pharmaceutical Industries Acquires Taiyo Pharmaceutical Industry 103

8.1.9 Teva Pharmaceutical Industries Acquires Corporacion Infarmasa 103

8.1.10 Teva Pharmaceutical Industries Completes Acquisition of ratiopharm 103

8.1.11 Teva Pharmaceutical Acquires Barr Pharmaceuticals 103

8.1.12 Teva Pharmaceutical Industries Signs Joint Venture Agreement with Kowa Company 104

8.1.13 Teva Pharmaceutical Acquires Bentley Pharmaceuticals 104

9 Generics in Antivirals Market to 2018 - Appendix 105

9.1 Market Definitions 105

9.2 Abbreviations 105

9.3 Sources 106

9.4 Research Methodology 106

9.4.1 Coverage 107

9.4.2 Secondary Research 107

9.4.3 Primary Research 107

9.4.4 Forecast 108

9.4.5 Expert Panel Validation 110

9.5 Contact Us 110

9.6 Disclaimer 110

 

1.1 List of Tables

Table 1: Generics in Antivirals Market, Global, Revenue by Indication ($m), 2004-2010 12

Table 2: Generics in Antivirals Market, Global, Revenue Forecast by Indication ($m), 2010-2018 13

Table 3: Generics in Antivirals Market, Global, Revenue ($bn), 2004-2010 14

Table 4: Generics in Antivirals Market, Global, Revenue Forecast ($bn), 2010-2018 15

Table 5: Generics in Antivirals Market, Global, Revenue by Geography ($m), 2004–2010 16

Table 6: Generics in Antivirals Market, Global, Revenue Forecast by Geography ($m), 2010-2018 17

Table 7: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2004-2010 18

Table 8: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2010-2018 18

Table 9: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2004–2018 19

Table 10: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2010-2018 20

Table 11: Generics in Antivirals Market, The US, Revenue ($m), 2004-2010 23

Table 12: Generics in Antivirals Market, The US, Revenue Forecast ($m), 2010-2018 23

Table 13: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2004–2010 24

Table 14: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2010-2018 24

Table 15: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue ($m), 2004-2010 26

Table 16: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast ($m), 2010-2018 26

Table 17: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue by Geography ($m), 2004–2010 27

Table 18: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast by Geography ($m), 2010-2018 27

Table 19: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004–2010 29

Table 20: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2010–2018 29

Table 21: Generics in Antivirals Market, Japan, Revenue ($m), 2004-2010 31

Table 22: Generics in Antivirals Market, Japan, Revenue Forecast ($m), 2010-2018 31

Table 23: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2004–2010 32

Table 24: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2010–2018 32

Table 25: Generics in HIV Market, Global, Revenue ($m), 2004-2010 35

Table 26: Generics in HIV Market, Global, Revenue Forecast ($m), 2010-2018 35

Table 27: Generics in HIV Market, Global, Patent Expiry of Major Products, 2010-2018 36

Table 28: Generics in HIV Market, Global, Revenue by Geography ($m), 2004–2010 38

Table 29: Generics in HIV Market, Global, Revenue Forecast by Geography ($m), 2010–2018 39

Table 30: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2004-2010 40

Table 31: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2010-2018 40

Table 32: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2004–2010 42

Table 33: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2010–2018 43

Table 34: Generics in Hepatitis Market, Global, Revenue ($m), 2004-2010 47

Table 35: Generics in Hepatitis Market, Global, Revenue Forecast ($m), 2010-2018 47

Table 36: Generics in Hepatitis Market, Global, Patent Expiry of Major Products, 2010-2018 48

Table 37: Generics in Hepatitis Market, Global, Revenue by Geography ($m), 2004–2010 49

Table 38: Generics in Hepatitis Market, Global, Revenue Forecast by Geography ($m), 2010–2018 50

Table 39: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2004-2010 51

Table 40: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2010-2018 51

Table 41: Generics in Hepatitis Market, Global, Treatment Usage Pattern ('000), 2004–2010 53

Table 42: Generics in Hepatitis Market, Global, Treatment Usage Pattern ('000), 2010–2018 54

Table 43: Generics in Herpes Therapeutics Market, Global, Revenue ($m), 2004-2010 58

Table 44: Generics in Herpes Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 58

Table 45: Generics in Herpes Therapeutics Market, Revenue by Geography ($m), 2004-2010 60

Table 46: Generics in Herpes Therapeutics Market, Revenue Forecast by Geography ($m), 2010-2018 61

Table 47: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 62

Table 48: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 62

Table 49: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004–2010 64

Table 50: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010–2018 64

Table 51: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue ($m), 2004-2010 68

Table 52: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 68

Table 53: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue by Geography ($m), 2004–2010 70

Table 54: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2010–2018 71

Table 55: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 72

Table 56: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 72

Table 57: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004–2010 73

Table 58: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2010–2018 73

Table 59: Generics in Influenza Therapeutics Market, Global, Revenue ($m), 2004-2010 77

Table 60: Generics in Influenza Therapeutics Market, Global, Revenue Forecast ($m), 2010-2018 77

Table 61: Generics in Influenza Therapeutics Market, Global, Revenue by Geography ($m), 2004–2010 79

Table 62: Generics in Influenza Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2010–2018 80

Table 63: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2010 81

Table 64: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018 81

Table 65: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004–2010 83

Table 66: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010–2018 83

Table 67: Generics in Influenza Therapeutics Market, List of Marketed Products Expecting Loss of Patent Exclusivity 91

 

1.2 List of Figures

Figure 1: Generics in Antivirals Market, Global, Revenue Forecast by Indication ($m), 2004-2018 12

Figure 2: Generics in Antivirals Market, Global, Revenue Forecast ($bn), 2004-2018 14

Figure 3: Generics in Antivirals Market, Global, Revenue Forecast by Geography ($m), 2004–2018 16

Figure 4: Generics in Antivirals Market, Global, Annual Cost of Treatment ($), 2004-2018 18

Figure 5: Generics in Antivirals Market, Global, Treatment Usage Pattern (millions), 2004–2018 19

Figure 6: Generics in Antivirals Market, Global, Drivers and Restraints 21

Figure 7: Generics in Antivirals Market, The US, Revenue Forecast ($m), 2004-2018 23

Figure 8: Generics in Antivirals Market, The US, Treatment Usage Pattern (millions), 2004–2018 24

Figure 9: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast ($m), 2004-2018 26

Figure 10: Generics in Antivirals Market, The Top Five Countries of Europe, Revenue Forecast by Geography ($m), 2004–2018 27

Figure 11: Generics in Antivirals Market, The Top Five Countries of Europe, Treatment Usage Pattern (millions), 2004–2018 29

Figure 12: Generics in Antivirals Market, Japan, Revenue Forecast ($m), 2004-2018 31

Figure 13: Generics in Antivirals Market, Japan, Treatment Usage Pattern (millions), 2004–2018 32

Figure 14: Generics in HIV Market, Global, Revenue Forecast ($m), 2004-2018 35

Figure 15: Generics in HIV Market, Global, Revenue Forecast by Geography ($m), 2004–2018 38

Figure 16: Generics in HIV Market, Global, Annual Cost of Treatment ($), 2004-2018 40

Figure 17: Generics in HIV Market, HIV/AIDS Treatment Flow Algorithm, 2011 41

Figure 18: Generics in HIV Market, Global, Treatment Usage Pattern ('000), 2004–2018 42

Figure 19: Generics in HIV Market, Global, Drivers and Restraints 44

Figure 20: Generics in Hepatitis Market, Global, Revenue Forecast ($m), 2004-2018 47

Figure 21: Generics in Hepatitis Market, Global, Revenue Forecast by Geography ($m), 2004–2018 49

Figure 22: Generics in Hepatitis Market, Global, Annual Cost of Treatment ($), 2004-2018 51

Figure 23: Generics in Hepatitis Market, Hepatitis Treatment Flow Pathway, 2011 52

Figure 24: Generics in Hepatitis Market, Global, Treatment Usage Pattern (millions), 2004–2018 53

Figure 25: Generics in Hepatitis Market, Global, Drivers and Restraints 55

Figure 26: Generics in Herpes Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 58

Figure 27: Generics in Herpes Therapeutics Market, Revenue Forecast by Geography ($m), 2004-2018 60

Figure 28: Generics in Herpes Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 62

Figure 29: Generics in Herpes Therapeutics Market, Global, Treatment Algorithm,2011 63

Figure 30: Generics in Herpes Therapeutics Market, Global, Treatment Usage Pattern (millions), 2004–2018 64

Figure 31: Generics in Herpes Therapeutics, Global, Drivers and Restraints 66

Figure 32: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 68

Figure 33: Generics in Cytomegalovirus Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2004–2018 70

Figure 34: Generics in Cytomegalovirus Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 72

Figure 35: Generics in Cytomegalovirus Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004–2018 73

Figure 36: Generics in Cytomegalovirus Therapeutics Market, Global, Drivers and Restraints 75

Figure 37: Generics in Influenza Therapeutics Market, Global, Revenue Forecast ($m), 2004-2018 77

Figure 38: Generics in Influenza Therapeutics Market, Global, Revenue Forecast by Geography ($m), 2004–2018 79

Figure 39: Generics in Influenza Therapeutics Market, Global, Annual Cost of Treatment ($), 2004-2018 81

Figure 40: Generics in Influenza Therapeutics Market, Treatment Flow Algorithm for Influenza, 2011 82

Figure 41: Generics in Influenza Therapeutics Market, Global, Treatment Usage Pattern ('000), 2004–2018 83

Figure 42: Generics in Influenza Therapeutics Market, Global, Drivers and Restraints 85

Figure 43: Generics in Antiviral Market, Teva Pharmaceuticals SWOT Profile, 2011 97

Figure 44: Generics in Antiviral Market, Aurobindo Pharma SWOT Profile, 2011 98

Figure 45: Generics in Antiviral Market, Watson Pharmaceuticals SWOT Profile, 2011 99

Figure 46: Generics in Antiviral Market, Mylan Inc SWOT Profile, 2011 100

Figure 47: GBI Research Market Forecasting Model 109

 

Companies mentioned
Teva Pharmaceuticals
Aurobindo Pharma Ltd
Watson Pharmaceuticals
Mylan Inc

To order this report: Therapy Industry: Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626



'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. MarketsandMarkets: Global Healthcare Cloud Computing Market Worth $5,419.8 Million by 2017
3. Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing
4. MarketsandMarkets: Global Radiotherapy Devices Market Worth $5.8 Billion by 2016
5. Market response to Kallo technology
6. India ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
7. Medical Imaging Information Systems Market to 2017 - Replacement of Legacy Systems and Advances in Software Present Growth Opportunities
8. Patient Monitoring Devices Market to 2017 - Increasing Use of Wireless Remote Patient Monitoring to be the Key Technology Trend
9. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
10. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
11. European Market for Peripheral Vascular Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016   TrainerMD , the first ... announced a new collaboration with Styku . Styku, ... leverages Microsoft Kinect hardware to provide users world-class, real-time 3D body ... now have the means to see, hear and feel their health ... , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
(Date:12/5/2016)... -- For the third consecutive year, Astellas has achieved ... Campaign Foundation,s (HRC) annual Corporate Equality Index ... used to rate companies on policies and practices concerning ... For the last 15 years, HRC has released ... efforts, culture and business practices. The survey rates business ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):